Risk stratification and prognostic factors in the post-myocardial infarction patient

The American Journal of Cardiology
Christopher P Cannon, Barry H Greenberg

Abstract

Among the 5 million patients presenting to emergency departments with chest pain each year in the United States, approximately 1 million are diagnosed with myocardial infarction (MI). Physicians have the difficult task of making decisions regarding admission and treatment and identifying patients at high risk for adverse outcomes, such as early mortality, left ventricular dysfunction (LVD), and heart failure. Several measures can be implemented in the process of risk assessment, including clinical judgment, electrocardiographic and echocardiographic findings, and the presence of biomarkers. Biomarkers--which can be classified as antecedent, screening, diagnostic, staging, or prognostic--may help identify the subset of patients who need early intervention and/or intensive therapy. Using a multimarker strategy that combines a marker of hemodynamic stress (brain natriuretic peptide) or of inflammation (C-reactive protein) with a marker of necrosis (cardiac troponin) may help to risk-stratify patients, guide treatment, and optimize admission and discharge decisions. This article discusses the potential benefits of risk assessment tools in the management of post-MI patients with LVD.

References

Jan 1, 1994·Annual Review of Medicine·Y Rozenman, M S Gotsman
Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Sep 19, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·R Latini, S Masson
Dec 8, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·G Bernardi
Jun 30, 2001·The New England Journal of Medicine·P M RidkerUNKNOWN Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators
Oct 6, 2001·The New England Journal of Medicine·J A de LemosE Braunwald
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Jul 24, 2003·Circulation·David A Morrow, Eugene Braunwald
Jan 28, 2004·Circulation·Philippe Gabriel StegUNKNOWN Global Registry of Acute Coronary Events Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Apr 15, 2005·The New England Journal of Medicine·Beth Cohen, David Singh
Nov 10, 2005·Cardiology Clinics·Christopher P Cannon
Jul 24, 2007·American Heart Journal·Soko SetoguchiSebastian Schneeweiss
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Sean M DonahoeElliott M Antman

❮ Previous
Next ❯

Citations

Nov 18, 2010·Environmental Health Perspectives·Victoria H ArrandaleTim K Takaro
Jul 16, 2014·Archivos de cardiología de México·Maximiliano de AbreuCarlos Tajer
Jan 15, 2014·Critical Reviews in Clinical Laboratory Sciences·Giuseppe Lippi, Gianfranco Cervellin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.